Explore the latest news from Khondrion and its team.
Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that its CEO Prof. dr. Jan Smeitink will present first results of Khondrion’s KHENERGY study at the Dutch Life Sciences Conference in Oss, The Netherlands, on November 22 at 10 am.
New Patents granted for Khondrion’s mitochondrial disease lead compound KH176 NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical...
Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical...
THE KHENERGYC STUDY: European Union EFRO grant to boost the development of Khondrion’s KH176 for children with mitochondrial...
Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes...
Press Release New EU research project REMIX joins forces between universities’ research facilities and Khondrion New EU...
We recently sat down with Kasey Woleben, Co-founder, and Sophia Zilber, Board Member and Patient Registry Director of Cure Mito Foundation, to talk...
As 2021 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the past year and the continued progress Khondrion has made in its development of...
Movement, the act or process of moving, the change of place or position or posture, is a complex process under the control of many different parts...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? Jan Smeitink and I have been colleagues since the...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? I first heard about Khondrion from CEO Jan...
Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...
